Coeliac Disease and Non-coeliac Gluten Sensitivity: A Clinical and Philosophical Discussion

Author(s):  
F. Borrell-Carrió ◽  
E. Peguero-Rodríguez ◽  
V. Morales-Hidalgo ◽  
J. Castellote-Alonso ◽  
A. Estany
2012 ◽  
Vol 71 (4) ◽  
pp. 576-580 ◽  
Author(s):  
Imran Aziz ◽  
David S. Sanders

The rise in gluten consumption over time has led to the increasing recognition of coeliac disease (CD) with associated complications. However, only recently has there been an appreciation that the spectrum of gluten-related disorders is greater than just CD, which may explain the growing global popularity in gluten-free products. Current literature suggests that a newly recognised clinical entity in the form of non-coeliac gluten sensitivity (NCGS) may be the most common gluten-related disorder encountered by healthcare professionals, although its exact prevalence is as yet unknown. This article will review the historical relationship between mankind and gluten as well as the progressive recognition that it is possible for gluten to have a deleterious effect on our health. To this effect we discuss the prevalence, diagnosis and complications of CD including the benefits derived from a gluten-free diet (GFD). Finally, we discuss our current understanding of NCGS, in addition to highlighting the need for further research to determine the extent, clinicopathological features and serological biomarkers to help recognise this emerging condition in clinical practice.


2020 ◽  
Vol 2 (3) ◽  
pp. 281-299
Author(s):  
Zoë Gilbey ◽  
Justine Bold

The aim of this review was to assess the effects of a gluten free diet (GFD) in the management of epilepsy in people with coeliac disease (CD) or gluten sensitivity (GS). A systematic approach was used to undertake a literature review. Five electronic databases (PubMed; Scopus; Google Scholar; Cochrane Epilepsy Group specialised register; Cochrane Register of Controlled Trails (CENTRAL) via the Cochrane Register of Online Trials) were searched using predetermined relevant search terms. In total, 668 articles were identified. Duplicates were removed and predefined inclusion and exclusion criteria were applied, and a PRISMA flow chart was produced. Data was extracted using Covidence software. Twelve studies on Epilepsy and CD involving a total of 70 participants were selected for analysis; narrative synthesis was used owing to the small sample sizes in the selected studies. None of the 12 studies meeting inclusion criteria investigated gluten sensitivity and epilepsy. All the included studies support a link between epilepsy and CD. GFD was effective in 44 out of 70 participants across the studies in terms of a reduction of seizures, reduction of antiepileptic drugs (AEDs) or normalisation of EEG pattern. A total of 44 participants showed a reduction in seizures (across eight studies) and complete cessation of seizures was reported in 22 participants. In general, the earlier the GFD is implemented after the onset of seizures, the better the likelihood of the GFD being successful in supporting control of seizures. Mechanisms linking gluten with epilepsy are not fully understood; possible hypotheses include gluten mediated toxicity, immune-induced cortical damage and malabsorption. Evidence suggests the effectiveness of a GFD in supporting the management of epilepsy in patients with CD, although the quality of evidence is low. There appears to be a growing number of neurologists who are prepared to advocate the use of a GFD. A multidisciplinary approaches and further research are recommended. It could be argued that when balancing potential treatments such as AEDs or surgery, a GFD has a low likelihood of harm.


2016 ◽  
Vol 32 (2) ◽  
pp. 120-127 ◽  
Author(s):  
Imran Aziz ◽  
Krit Dwivedi ◽  
David S. Sanders

2019 ◽  
Vol 131 (7) ◽  
pp. 496-500 ◽  
Author(s):  
Panagiotis Zis ◽  
Ptolemaios Georgios Sarrigiannis ◽  
Dasappaiah Ganesh Rao ◽  
David Surendran Sanders ◽  
Marios Hadjivassiliou

2015 ◽  
Vol 60 (4) ◽  
pp. 429-432 ◽  
Author(s):  
Caroline R. Meijer ◽  
Raanan Shamir ◽  
Maria L. Mearin

Nutrients ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1711 ◽  
Author(s):  
Annalisa Schiepatti ◽  
Jessica Savioli ◽  
Marta Vernero ◽  
Federica Borrelli de Andreis ◽  
Luca Perfetti ◽  
...  

The spectrum of gluten-related disorders (GRD) has emerged as a relevant phenomenon possibly impacting on health care procedures and costs worldwide. Current classification of GRD is mainly based on their pathophysiology, and the following categories can be distinguished: immune-mediated disorders that include coeliac disease (CD), dermatitis herpetiformis (DH), and gluten ataxia (GA); allergic reactions such as wheat allergy (WA); and non-coeliac gluten sensitivity (NCGS), a condition characterized by both gastrointestinal and extra-intestinal symptoms subjectively believed to be induced by the ingestion of gluten/wheat that has recently gained popularity. Although CD, DH, and WA are well-defined clinical entities, whose diagnosis is based on specific diagnostic criteria, a diagnosis of NCGS may on the contrary be considered only after the exclusion of other organic disorders. Neither allergic nor autoimmune mechanisms have been found to be involved in NCGS. Mistakes in the diagnosis of GRD are still a relevant clinical problem that may result in overtreatment of patients being unnecessary started on a gluten-free diet and waste of health-care resources. On the basis of our clinical experience and literature, we aim to identify the main pitfalls in the diagnosis of CD and its complications, DH, and WA. We provide a practical methodological approach to guide clinicians on how to recognize and avoid them.


Sign in / Sign up

Export Citation Format

Share Document